Hemab, still play­ing coy, gets its first ma­jor fundraise for he­mo­phil­ia bis­pecifics

A com­pa­ny seed­ed by No­vo’s in­cu­ba­tor at the end of 2020 is tak­ing its next step Thurs­day, emerg­ing in­to the he­mo­phil­ia space with a hefty Se­ries A.

The Dan­ish biotech Hemab is putting the bow on a $55 mil­lion round ear­ly Thurs­day, raised with mon­ey from No­vo Seeds as well as promi­nent in­vestor RA Cap­i­tal. See­ing RA in­vest as ear­ly as a Se­ries A rais­es the nat­ur­al sus­pi­cion of a po­ten­tial IPO, and new­ly-ap­point­ed CEO Ben­ny Sorensen told End­points News he’d hoped to be asked about it.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.